Regal Assets Analytics

Bill Langbein

Marinus Pharma’s Epilepsy Drug Shows Promise; SanaCurrents Closing Out Coverage

By |2021-03-15T15:58:12-04:00March 15th, 2021|Categories: Bill Langbein, SanaCurrents, SanaCurrents Updates|Tags: |

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) disclosed results of its phase II [...]

AnaptysBio (ANAB) Probability Sentiment

By |2021-01-31T17:44:12-05:00January 29th, 2021|Categories: Bill Langbein, Healthcare, Pharmaceutical & Biotechnology, SanaCurrents, SanaCurrents Probability Sentiment|Tags: |

Anaptysbio, Inc. (NASDAQ:ANAB) Probability Sentiment [...]

FDA Decision On Aurinia’s Lupus Drug Likely To Be Announced Prior To January 26, 2021 Trading

By |2021-01-24T16:37:59-05:00January 24th, 2021|Categories: Bill Langbein, SanaCurrents, SanaCurrents Updates|Tags: |

As of mid-day trading on January 22, Aurinia Pharmaceuticals Inc [...]

Go to Top